Jefferies Reiterates Buy Rating on DexCom (DXCM) After FDA Cleared Stelo
Tweet Send to a Friend
Jefferies analyst Matthew Taylor reiterated a Buy rating and $160.00 price target on DexCom (NASDAQ: DXCM).The analyst commented, "On 3.5.24 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
